Low doses of IL-2 in combination with DC vaccination are able to expand CD4+CD25+Foxp3+ Treg cells in metastatic renal cell carcinoma patients suggesting that a combination of DCS-mediated immunotherapy and Treg depletion may be a promising approach in enhancing the ability of vaccination therapy to elicit effective anti-tumor responses in cancer patients. This evidence concerns the gene FOXP3 and neoplasm.